Pathfinder Cell Therapy, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFND research report →
About the company
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs.
- CEO
- Richard L. Franklin
- IPO
- 2000
- Employees
- 1
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $66.72K
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -4.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 31.81%
- ROIC
- 116.56%
- Revenue
- $0 · -100.00%
- Net Income
- $-1,669,000 · 7.84%
- EPS
- $-0.00 · 7.41%
- Op Income
- $-1,119,000
- FCF YoY
- 39.85%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -24.33
- Avg Volume
- 368
Get TickerSpark's AI analysis on PFND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PFND coverage
Recent articles, reports, and earnings notes.
No research on PFND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PFND report →Similar companies
Peers in the same neighborhood.